News
PHVS
16.67
-1.42%
-0.24
Pharvaris (PHVS) Gets a Buy from Morgan Stanley
TipRanks · 4d ago
Weekly Report: what happened at PHVS last week (0303-0307)?
Weekly Report · 4d ago
Pharvaris Price Target Maintained With a $55.00/Share by Citizens Capital Markets
Dow Jones · 03/03 15:20
Citizens Capital Markets Reiterates Market Outperform on Pharvaris, Maintains $55 Price Target
Benzinga · 03/03 15:10
Morgan Stanley Remains a Buy on Pharvaris (PHVS)
TipRanks · 03/03 13:07
Pharvaris reports safety and efficacy data of deucrictibant
TipRanks · 03/03 11:55
Pharvaris Showcases Phase 3 Data on Deucrictibant for Hereditary Angioedema at AAAAI-WAO Congress
Benzinga · 03/03 11:52
Weekly Report: what happened at PHVS last week (0224-0228)?
Weekly Report · 03/03 09:22
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Barchart · 03/03 05:50
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Barchart · 03/03 05:48
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)
TipRanks · 03/03 05:40
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
Seeking Alpha · 02/26 12:45
Morgan Stanley Remains a Buy on Pharvaris (PHVS)
TipRanks · 02/24 13:19
Weekly Report: what happened at PHVS last week (0217-0221)?
Weekly Report · 02/24 09:22
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 02/18 13:16
Weekly Report: what happened at PHVS last week (0210-0214)?
Weekly Report · 02/17 09:21
Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)
TipRanks · 02/10 13:26
Weekly Report: what happened at PHVS last week (0203-0207)?
Weekly Report · 02/10 09:20
Morgan Stanley Remains a Buy on Pharvaris (PHVS)
TipRanks · 02/03 13:38
Weekly Report: what happened at PHVS last week (0127-0131)?
Weekly Report · 02/03 09:21
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
More
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.